CURRENT SERIES:
Managing Challenges of Insomnia in Elderly Patients
October 14, 2019
October 15, 2019
October 22, 2019
October 22, 2019
October 29, 2019
October 29, 2019
November 05, 2019
November 05, 2019
November 12, 2019
November 12, 2019
November 21, 2019
November 21, 2019
NOW PLAYING
The Impact of DORA Treatment
13 of 14
November 27, 2019

The Impact of DORA Treatment

Peter L. Salgo, MD, leads a discussion on the suvorexant study involving patients with Alzheimer disease, and its implications for the treatment of patients with insomnia.


Peter L. Salgo, MD: Now, I know there was a study for suvorexant in patients with Alzheimer’s disease. That’s ongoing as I understand, or is that complete?

Nicole Brandt, PharmD, MBA, BCPP, CGP, FASCP: There was a poster presented at the American Academy of Neurology, and I think the lead author on that was Dr W. Joseph Herring, MD, PhD. It looked specifically at the clinical polysomnograph. I’m going to butcher this for a second.

Peter L. Salgo, MD: Polysomnograph.

Nicole Brandt, PharmD, MBA, BCPP, CGP, FASCP: Thank you, polysomnograph. Are we saying polysomnograph or polysomnography?

Sanford H. Auerbach, MD: PSG.

Nicole Brandt, PharmD, MBA, BCPP, CGP, FASCP: What?

Sanford H. Auerbach, MD: PSG.

Peter L. Salgo, MD: Just go with PSG.

Nicole Brandt, PharmD, MBA, BCPP, CGP, FASCP: Thank you, PSG. They actually use that in terms of looking at the implication of suvorexant on that in patients with Alzheimer’s disease. The patient population with Alzheimer’s disease were those with mild to moderate stage, and the interesting aspect of that is many were more in the mild stage. The average Mini-Mental State Exam score was about a 22. I think as the experts on the panel know, as the disease progresses, sometimes the sleep becomes a manifestation of other problems as well. But nonetheless, they saw an improvement in total sleep time of about 29 minutes. And again, we’re seeing a range.

Getting to Sandy’s point in terms of the next day, the signal at least didn’t seem to have an implication on their cognition or that drowsiness. But it was a short study—a 4-week trial. There’s still ongoing enrollment. It had a 142 patient cohort. They looked at some of the adverse events, and of course next-day somnolence, but the dropout was pretty low. It’s a poster—I haven’t seen the whole publication— but it does give us something to look at in a population that we’re caring for, especially if we don’t see that implication on the next day. But I think we’ll have to watch in terms of the implication on other safety parameters, too.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up